ESMO Congress 2021

Phase III data highlight the consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer patients, with greatest benefit in high PD-L1-expressing tumours

The efficacy and overall good tolerability of cyclin-dependent kinase (CDK) 4/6 inhibitors have led to a change in the therapeutic algorithm  of HR-positive/HER2-negative advanced breast cancer and established these compounds as the gold standard option for any patient with metastatic disease, except those with visceral crisis.

Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer

Two phase I trials in patients with advanced EGFR-mutated NSCLC demonstrate promising potential of targeted therapy with amivantamab plus lazertinib

Positive in vitro and in vivo antitumour effects in breast and lung cancer models and in mismatch repair-driven cancer models

Significant, but clinically modest, prolongation of radiographic progression-free survival and event-free survival was achieved with darolutamide in the SAKK 08/16 study

Addition of abiraterone acetate plus prednisone shows clear survival improvements in castration-sensitive prostate cancer

Good response rate and disease control with adagrasib and sotorasib in combination therapy shown in early-stage trials

Final overall survival results from the KEYNOTE-355 study confirm immune checkpoint inhibitors as the first-line treatment of choice in women with metastatic or relapsing disease

Results from the SAKK 01/10 trial demonstrate favourable progression-free survival and low toxicity with single-dose carboplatin and involved-node radiotherapy